For the first voting question, panelists by a 5-3 margin voted that the benefit-risk of belantamab in combination with bortezomib (Velcade) and dexamethasone (BVd) -- evaluated in DREAMM-7 -- is ...

These four dividend stocks are ideal choices for growth and income investors seeking reliable passive income with some growth potential.

Four well-known dividend stocks are ideal choices for growth and income investors seeking reliable passive income with some growth potential to keep pace with inflation.

Researchers determined salvage high-dose chemotherapy, ASCT, and lenalidomide maintenance does not appear to improve OS outcomes in relapsed/refractory MM.

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

BMY is already facing top-line pressure as the legacy portfolio is under pressure due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane.